Ariel Capital Advisors LLC Purchases Shares of 12,553 Amgen Inc. (AMGN)
Ariel Capital Advisors LLC bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, Holdings Channel reports. The firm bought 12,553 shares of the medical research company’s stock, valued at approximately $1,910,000.
Several other institutional investors have also recently bought and sold shares of the stock. Telemus Capital LLC bought a new stake in Amgen during the first quarter worth about $2,917,000. River Wealth Advisors LLC boosted its stake in Amgen by 10.1% in the first quarter. River Wealth Advisors LLC now owns 12,487 shares of the medical research company’s stock worth $1,872,000 after buying an additional 1,144 shares in the last quarter. Commonwealth Equity Services Inc boosted its stake in Amgen by 3.0% in the first quarter. Commonwealth Equity Services Inc now owns 181,502 shares of the medical research company’s stock worth $27,213,000 after buying an additional 5,302 shares in the last quarter. Aperio Group LLC boosted its stake in Amgen by 2.3% in the first quarter. Aperio Group LLC now owns 318,298 shares of the medical research company’s stock worth $47,722,000 after buying an additional 7,110 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. bought a new stake in Amgen during the first quarter worth about $2,488,000. 79.15% of the stock is owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 0.28% during trading on Wednesday, reaching $163.86. The company had a trading volume of 1,941,337 shares. Amgen Inc. has a 52-week low of $139.02 and a 52-week high of $176.85. The company has a market capitalization of $122.63 billion, a P/E ratio of 16.77 and a beta of 0.94. The firm has a 50-day moving average price of $170.32 and a 200-day moving average price of $162.15.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The company earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. During the same quarter in the previous year, the firm posted $2.57 EPS. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. On average, analysts predict that Amgen Inc. will post $11.35 EPS for the current fiscal year.
AMGN has been the topic of a number of research analyst reports. Goldman Sachs Group Inc. reissued a “buy” rating and issued a $202.00 price target on shares of Amgen in a research note on Wednesday, June 15th. Leerink Swann reissued a “hold” rating on shares of Amgen in a research note on Sunday, June 26th. Sanford C. Bernstein initiated coverage on shares of Amgen in a research note on Wednesday, June 29th. They set a “market perform” rating and a $161.00 target price on the stock. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $166.00 target price on the stock in a research note on Wednesday, June 29th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Amgen in a research note on Wednesday, June 29th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $184.94.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the business’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.